N-Glycosylated type Ⅱ collagen peptides as therapeutic saccharide vaccines for rheumatoid arthritis
作者机构:State Key Laboratory of Natural and Biomimetic DrugsSchool of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Rheumatology and ImmunologyPeking University People’s HospitalBeijing 100044China
出 版 物:《Chinese Chemical Letters》 (中国化学快报(英文版))
年 卷 期:2024年第35卷第5期
页 面:197-200页
核心收录:
学科分类:1007[医学-药学(可授医学、理学学位)] 10[医学]
基 金:supported by the National Natural Science Foundation of China(Nos.81930097,21977005,82151223) supported by the National Key R&D Program of China(No.2022YFF1203005)
主 题:Rheumatoid arthritis TypeⅡcollegan Glycosylation N-Glycosylated altered peptides Saccharide vaccines
摘 要:The interaction among type Ⅱ collagen(CⅡ),human DR4 major histocompatibility complex type Ⅱ molecule(MHC Ⅱ)and T-cell receptor(TCR)is associated with the development of rheumatoid arthritis(RA).The activation of T cells can be reduced through exposure to modified CⅡ(263-272)glycopeptide fragment via competitive inhibition with *** this work,30 peptides based on the sequence of CⅡ(263-272)were prepared and evaluated for their binding to DR4 protein by surface plasmon resonance(SPR)*** effect on the secretion of pro-inflammatory factors by the spleen cells in collagen induced rheumatoid arthritis(CIA)mouse was also *** N-glycosylated CⅡ peptides were identified to have strong binding to the human recombinant DR4 protein and weak proinflammatory *** glycopeptides could be developed as therapeutic saccharide vaccines for the treatment of rheumatoid arthritis(RA).